Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_curated type ECO_0000205 NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- source_evidence_curated label "DisGeNET evidence - CURATED" NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- source_evidence_curated comment "Gene-disease associations manually curated." NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_assertion description "[The persistent mA1/4llerian duct syndrome, characterized by the lack of regression of mA1/4llerian derivatives, uterus and tubes in otherwise normally masculinized males, is a genetically transmitted disorder implicating either anti-mA1/4llerian hormone (AMH), a member of the transforming growth factor-beta superfamily, or its type II receptor, a serine/threonine kinase homologous to the receptors of other members of the transforming growth factor-beta superfamily.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_assertion evidence source_evidence_curated NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_assertion SIO_000772 8872466 NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_assertion wasDerivedFrom uniprot-20150221 NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_assertion wasGeneratedBy ECO_0000218 NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.
- uniprot-20150221 importedOn "2015-02-21" NP957.RAZu_YelwKo-VToLGEd2CKuusJGptSaQ-rVc77mqYtl6E130_provenance.